EGI
MRNS

EAM Global Investors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

EAM Global Investors’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-27,742
Closed -$905K – 175
2017
Q4 		$905K Buy
+27,742
New +$748K 0.46% 104

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
TBC
Three Bays Capital Boston, Massachusetts $848M AUM 7.41% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM Global Investors's MRNS Position: Q1 2018 in Review

EAM Global Investors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2018, closing a stake of 27,742 shares — an estimated $905K sold.

EAM Global Investors first reported a position in MRNS in Q4 2017 and held it in 1 quarter. The position peaked at $905K in Q4 2017. 60 funds tracked by Wall St. Rank hold MRNS as of Q1 2018.

  • EAM Global Investors reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2018 after selling out during the quarter.
  • EAM Global Investors sold 27,742 Marinus Pharmaceuticals, Inc shares in Q1 2018, an estimated $905K.
  • EAM Global Investors first reported a position in Marinus Pharmaceuticals, Inc in Q4 2017 and held it in 1 quarter.
  • EAM Global Investors's Marinus Pharmaceuticals, Inc position peaked at $905K in Q4 2017.
  • 60 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2018.

Based on EAM Global Investors's 13F filing for Q1 2018, filed 4 Jun 2018.